JCO global oncology · 2025
Epidemiology and Survival of Marginal Zone Lymphoma in Colombian Patients: An Observational Retrospective Study.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Combariza-Vallejo Juan F, Orduz-Rodriguez Rocío, Gomez-Lopera Natalia, Colmenares-Mejia Claudia C, Benavides-Rojas Monica S, Calderon-Ortega Yesica M, Godoy-Corredor Marcela, Isaza-Ruget Mario Arturo
Аннотация
PURPOSE: Marginal zone lymphomas (MZLs) are indolent non-Hodgkin lymphomas, categorized into three subtypes: extranodal, splenic, and nodal MZL (NMZL). MZL epidemiology and outcomes in Latin America remain underexplored.
MATERIALS AND METHODS: This retrospective cohort study included patients with MZL in Colombia from 2000 to 2023. Patients were followed for at least 24 months from diagnosis. The primary outcomes were real-world overall survival (Rw-OS) and real-world progression-free survival (Rw-PFS).
RESULTS: The cohort included 103 patients (63.1% female, 36.9% male) with a median age of 61.8 years. MALT lymphoma was the most common subtype (61.1%), followed by splenic MZL (26.2%) and NMZL (12.7%). The 60-month Rw-OS was 86.4%, and the Rw-PFS was 77.2%.
CONCLUSION: MZL in Colombian patients exhibits varied clinical presentations and survival outcomes. This study underscores the importance of early detection and subtype-specific management of MZL.
MATERIALS AND METHODS: This retrospective cohort study included patients with MZL in Colombia from 2000 to 2023. Patients were followed for at least 24 months from diagnosis. The primary outcomes were real-world overall survival (Rw-OS) and real-world progression-free survival (Rw-PFS).
RESULTS: The cohort included 103 patients (63.1% female, 36.9% male) with a median age of 61.8 years. MALT lymphoma was the most common subtype (61.1%), followed by splenic MZL (26.2%) and NMZL (12.7%). The 60-month Rw-OS was 86.4%, and the Rw-PFS was 77.2%.
CONCLUSION: MZL in Colombian patients exhibits varied clinical presentations and survival outcomes. This study underscores the importance of early detection and subtype-specific management of MZL.